Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Checkpoint Therapeutics, Inc is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Checkpoint Therapeutics employs 10 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.68|
|52-week range||$1.90 - $5.38|
|50-day moving average||$2.89|
|200-day moving average||$3.05|
|Wall St. target price||$15.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.01|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||-11.84%|
|3 months (2021-05-04)||-2.19%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
|Gross profit TTM||$-15,283,000|
|Return on assets TTM||-38.96%|
|Return on equity TTM||-74.74%|
|Market capitalisation||$220.1 million|
TTM: trailing 12 months
There are currently 2.4 million Checkpoint Therapeutics shares held short by investors – that's known as Checkpoint Therapeutics's "short interest". This figure is 20.5% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Checkpoint Therapeutics shares can be evaluated.
Checkpoint Therapeutics's "short interest ratio" (SIR) is the quantity of Checkpoint Therapeutics shares currently shorted divided by the average quantity of Checkpoint Therapeutics shares traded daily (recently around 1.4 million). Checkpoint Therapeutics's SIR currently stands at 1.75. In other words for every 100,000 Checkpoint Therapeutics shares traded daily on the market, roughly 1750 shares are currently held short.
However Checkpoint Therapeutics's short interest can also be evaluated against the total number of Checkpoint Therapeutics shares, or, against the total number of tradable Checkpoint Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Checkpoint Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Checkpoint Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0406% of the tradable shares (for every 100,000 tradable Checkpoint Therapeutics shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Checkpoint Therapeutics.
Find out more about how you can short Checkpoint Therapeutics stock.
We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $1.9 up to $5.376. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.6577. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Checkpoint Therapeutics, Inc. , a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7. 1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.